{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:15:38Z","timestamp":1770070538796,"version":"3.49.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["400176"],"award-info":[{"award-number":["400176"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.neuropharm.2014.11.004","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T19:25:22Z","timestamp":1416597922000},"page":"42-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["\u03b14\u03b22 nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: Implications for cognitive dysfunction in schizophrenia"],"prefix":"10.1016","volume":"90","author":[{"given":"Jacob M.","family":"Cloke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyer D.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.11.004_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0269881107067097","article-title":"Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat","volume":"21","author":"Abdul-Monim","year":"2007","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0006-3223(86)90244-1","article-title":"Neurophysiological studies of sensory gating in rats: effects of amphetamine, phencyclidine, and haloperidol","volume":"21","author":"Adler","year":"1986","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bbr.2012.03.024","article-title":"Object recognition testing: statistical considerations","volume":"232","author":"Akkerman","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib5","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1152\/jn.2001.86.6.3043","article-title":"Nicotinic acetylcholine receptor \u03b1 7 and \u03b14 \u03b22 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus","volume":"86","author":"Alkondon","year":"2001","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1523\/JNEUROSCI.20-01-00066.2000","article-title":"Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks","volume":"20","author":"Alkondon","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib7","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/cercor\/bhp214","article-title":"Tonic modulation of GABA release by nicotinic acetylcholine receptors in layer V of the murine prefrontal cortex","volume":"20","author":"Aracri","year":"2010","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib8","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1523\/JNEUROSCI.5171-06.2007","article-title":"Perceptual functions of perirhinal cortex in rats: zero-delay object recognition and simultaneous oddity discriminations","volume":"27","author":"Bartko","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0920-9964(96)00122-3","article-title":"Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics","volume":"24","author":"Beasley","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0006-3223(02)01360-4","article-title":"Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins","volume":"52","author":"Beasley","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib11","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1126\/science.1148045","article-title":"Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase","volume":"318","author":"Behrens","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1017\/S1121189X00001561","article-title":"Orbitofrontal cortex abnormalities in schizophrenia","volume":"19","author":"Bellani","year":"2010","journal-title":"Epidemiol. Psychiatric Sci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib13","first-page":"1006","article-title":"Sensory input deficits and negative symptoms in schizophrenic patients","volume":"126","author":"Braff","year":"1989","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.biopsych.2010.09.052","article-title":"A\u00a0randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia","volume":"69","author":"Buchanan","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopsych.2008.03.023","article-title":"Visual perception and its impairment in schizophrenia","volume":"64","author":"Butler","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/mp.2011.31","article-title":"A\u00a0critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior","volume":"17","author":"Carl\u00e9n","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.npp.1300031","article-title":"Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs","volume":"28","author":"Cochran","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature12755","article-title":"Prefrontal parvalbumin interneurons shape neuronal activity to drive fear expression","volume":"505","author":"Courtin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-010-2039-9","article-title":"Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia","volume":"214","author":"Damgaard","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/cercor\/bhs322","article-title":"Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks","volume":"24","author":"Dawson","year":"2014","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0920-9964(01)00344-9","article-title":"Audio-visual integration in schizophrenia","volume":"59","author":"de Gelder","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.schres.2004.02.013","article-title":"Multisensory integration of emotional faces and voices in schizophrenics","volume":"72","author":"de Gelder","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2010.04.010","article-title":"Modality-specific attention and multisensory integration of emotions in schizophrenia: reduced regulatory effects","volume":"122","author":"de Jong","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.schres.2008.10.001","article-title":"Audiovisual emotion recognition in schizophrenia: reduced integration of facial and vocal affect","volume":"107","author":"de Jong","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbr.2004.05.016","article-title":"Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats","volume":"156","author":"de Lima","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0166-4328(98)00079-5","article-title":"Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition","volume":"99","author":"Dix","year":"1999","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3940(00)01144-7","article-title":"Human post-mortem striatal alpha4 beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome","volume":"287","author":"Durany","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bbr.2009.12.036","article-title":"One-trial object recognition in rats and mice: methodological and theoretical issues","volume":"215","author":"Ennaceur","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A\u00a0new one-trial test for neurobiological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.61.2.119","article-title":"Acquiring and inhibiting prepotent responses in schizophrenia","volume":"61","author":"Ford","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tisssue for decreased numbers of hippocampal nicotinic receptors in schizophrenia","volume":"38","author":"Freedman","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib32","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib33","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.neuropharm.2011.03.015","article-title":"NMDA receptors, cognition and schizophrenia \u2013 testing the validity of the NMDA receptor hypofunction hypothesis","volume":"62","author":"Gilmour","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib34","first-page":"3","article-title":"The involvement of distraction in memory deficits induced by NMDAR antagonism: relevance to cognitive deficits in schizophrenia","author":"Grayson","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","article-title":"Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS","volume":"72","author":"Green","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1037\/1064-1297.8.2.207","article-title":"An assessment and comparison of the effects of oxotremorine, D-cyloserine, and bicuculline on delayed matching-to-sample performance in rats","volume":"8","author":"Harper","year":"2000","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711","volume":"63","author":"Hashimoto","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib38","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.bcp.2009.05.030","article-title":"TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia","volume":"78","author":"Hauser","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1101\/lm.032516.113","article-title":"Dysgranular retrosplenial cortex lesions in rats disrupt cross-modal object recognition","volume":"21","author":"Hindley","year":"2014","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib40","doi-asserted-by":"crossref","first-page":"18041","DOI":"10.1073\/pnas.0806669105","article-title":"Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs","volume":"105","author":"Homayoun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib41","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","article-title":"Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder","volume":"68","author":"Hong","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib42","first-page":"209","article-title":"Effect of phencyclidine in chronic schizophrenics","volume":"12","author":"Itil","year":"1967","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib43","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1038\/npp.2012.84","article-title":"Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia","volume":"37","author":"Jacklin","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/npp.2011.199","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia","volume":"37","author":"Jones","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.11.015","article-title":"Orbitofrontal cortex abnormality and deficit schizophrenia","volume":"143","author":"Kanahara","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbr.2014.07.017","article-title":"Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia","volume":"272","author":"Karamihalev","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.neuroscience.2004.03.039","article-title":"Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia","volume":"126","author":"Keilhoff","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.neuron.2010.09.017","article-title":"NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory","volume":"68","author":"Korotkova","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-005-0164-7","article-title":"Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization","volume":"184","author":"Levin","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib52","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1176\/appi.ajp.2008.08030395","article-title":"Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia","volume":"165","author":"Lewis","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tins.2011.10.004","article-title":"Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia","volume":"35","author":"Lewis","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib55","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/npp.2012.259","article-title":"A\u00a0randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia","volume":"38","author":"Lieberman","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib56","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1523\/JNEUROSCI.5419-08.2009","article-title":"A\u00a0loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia","volume":"29","author":"Lodge","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archneurpsyc.1959.02340150095011","article-title":"Study of a new schizophrenomimetic drug; sernyl","volume":"81","author":"Luby","year":"1959","journal-title":"Arch. Neurol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00213-011-2536-5","article-title":"Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models","volume":"220","author":"Lyon","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib59","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/npp.2011.21","article-title":"Selective alpha4beta2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons","volume":"36","author":"Maloku","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib60","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.neuropharm.2012.01.008","article-title":"Nicotinic receptor activation in perirhinal cortex and hippocampus enhances object memory in rats","volume":"62","author":"Melichercik","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib61","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.64.2.156","article-title":"Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia","volume":"64","author":"Menzies","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib64","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.neuron.2013.06.010","article-title":"Cellular and synaptic architecture of multisensory integration in the mouse neocortex","volume":"79","author":"Olcese","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib65","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","article-title":"Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia","volume":"63","author":"Olincy","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J.\u00a0Psychiatric Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.comppsych.2008.06.004","article-title":"Differences in audiovisual integration, as measured by McGurk phenomenon, among adult and adolescent patients with schizophrenia and age-matched healthy control groups","volume":"50","author":"Pearl","year":"2009","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.npp.1301188","article-title":"SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia","volume":"32","author":"Pichat","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl.\u00a0l","key":"10.1016\/j.neuropharm.2014.11.004_bib69","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1038\/bjp.2008.24","article-title":"Modelling prefrontal cortex deficits in schizophrenia: implications for treatment","volume":"153","author":"Pratt","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib70","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1749-6632.1999.tb11332.x","article-title":"Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons","volume":"868","author":"Radcliffe","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib71","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/138161210790170166","article-title":"Treating cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists","volume":"16","author":"Radek","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00213-006-0394-3","article-title":"Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA\/2 mouse model of sensory gating","volume":"187","author":"Radek","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib73","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.nlm.2012.09.001","article-title":"Crossmodal object recognition in rats with and without multimodal object pre-exposure: no effect of hippocampal lesions","volume":"98","author":"Reid","year":"2012","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib74","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/cercor\/bht061","article-title":"Delineating prefrontal cortex region contributions to crossmodal object recognition in rats","volume":"24","author":"Reid","year":"2013","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib75","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00213-011-2268-6","article-title":"Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia","volume":"217","author":"Romon","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib76","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2007.08.008","article-title":"Impaired multisensory processing in schizophrenia: deficits in the visual enhancement of speech comprehension under noisy environmental conditions","volume":"97","author":"Ross","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib77","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/npp.2011.224","article-title":"Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure","volume":"36","author":"Rushforth","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neulet.2013.06.040","article-title":"Chronic ketamine produces altered distribution of parvalbumin-positive cells in the hippocampus of adult rats","volume":"550","author":"Sabbagh","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tins.2008.05.002","article-title":"Crossmodal binding through neural coherence: implications for multisensory processing","volume":"31","author":"Senkowski","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib80","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2009.02.001","article-title":"Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder","volume":"110","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib82","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nature07991","article-title":"Parvalbumin neurons and gamma rhythms enhance cortical circuit performance","volume":"459","author":"Sohal","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib83","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.schres.2013.04.038","article-title":"Deficient multisensory integration in schizophrenia: an event-related potential study","volume":"147","author":"Stekelenburg","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib84","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.neuropsychologia.2011.07.017","article-title":"Unisensory processing and multisensory integration in schizophrenia: a high-density electrical mapping study","volume":"49","author":"Stone","year":"2011","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib85","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.neuropharm.2009.02.003","article-title":"alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment","volume":"56","author":"Thomsen","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib86","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.107.120436","article-title":"An allosteric modulator of the alpha 7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in\u00a0vivo","volume":"323","author":"Timmermann","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuroscience.2011.08.038","article-title":"Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia","volume":"195","author":"Timofeeva","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib88","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrn2774","article-title":"Abnormal neural oscillations and synchrony in schizophrenia","volume":"11","author":"Uhlhaas","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib89","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/npp.2014.17","article-title":"A\u00a0randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia","volume":"39","author":"Umbricht","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib90","first-page":"964","article-title":"Spatial integration in mouse primary visual cortex","volume":"110","author":"Vaicelinunaite","year":"2013","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib91","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2011.10.004","article-title":"Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia","volume":"134","author":"Velligan","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.psychres.2009.01.025","article-title":"Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study","volume":"175","author":"Waldo","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib93","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/jpet.110.171892","article-title":"RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents","volume":"336","author":"Wallace","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2008.06.007","article-title":"Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA\/2 mice","volume":"1224","author":"Wildeboer","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib95","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1016\/j.neuropsychologia.2010.06.028","article-title":"Reduced multisensory integration in patients with schizophrenia on a target detection task","volume":"48","author":"Williams","year":"2010","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib96","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1523\/JNEUROSCI.1346-04.2004","article-title":"Double dissociation between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe","volume":"24","author":"Winters","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib97","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1523\/JNEUROSCI.6073-09.2010","article-title":"A\u00a0distributed cortical representation underlies crossmodal object recognition in rats","volume":"30","author":"Winters","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib98","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1523\/JNEUROSCI.6377-11.2012","article-title":"Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs","volume":"32","author":"Wood","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib99","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","article-title":"Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia","volume":"122","author":"Young","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib100","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1176\/appi.ajp.2012.11081289","article-title":"Short-term tropisetron treatment and cognitive and p50 auditory gating deficits in schizophrenia","volume":"169","author":"Zhang","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.004_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00188-8","article-title":"A\u00a0selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia","volume":"55","author":"Zhang","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2014.11.004_bib102","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3389\/fnhum.2013.00674","article-title":"Attention and multisensory integration of emotions in schizophrenia","volume":"7","author":"Zvyagintsev","year":"2013","journal-title":"Front. Hum. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814004080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814004080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T03:12:52Z","timestamp":1650683572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814004080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":102,"alternative-id":["S0028390814004080"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.11.004","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b14\u03b22 nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: Implications for cognitive dysfunction in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}